HYPOTHESIS There is evidence of the existence of social cognition (SC) dysfunctions in patients with SUD, and its potential implications in the etiopathogenesis, clinical course, and response to treatment have been postulated. At the healthcare level, SC should be taken into account in diagnostic and therapeutic procedures.
The detection of SC dysfunctions and the implementation of specific treatment for them will contribute to improving the therapeutic response of patients with SUD.
The general hypotheses of the study will be:
1. A high percentage of people with dual pathology and impairment of social cognition will be detected.
2. People with dual pathology and impairment of social cognition will improve after the intervention with the updated version of ET®.
3. A panel of potential biomarkers that predict therapeutic response can be identified.
GENERAL OBJECTIVES:
1. Determine the prevalence of dual pathology in clinical and prison samples of people with SUD.
2. Evaluate the presence of alterations in the domains that make up social cognition (SC) in people with dual pathology in clinical and prison samples.
3. Check the effectiveness of a computerized rehabilitation program for SC, the ET® program, in people with dual pathology who present SC dysfunctions.
4. Develop a panel of biomarkers in saliva that predicts which people with dual pathology will benefit from training, using shotgun mass spectrometry techniques (LC-ESI-MS/MS).
5. Conduct the study taking into account the gender perspective.
SPECIFIC OBJECTIVES:
1.1 Assess the prevalence of mental disorders in people with an addictive disorder.
1.2 Evaluate the differences in clinical and penitentiary environments of mental disorders in people with an addictive disorder.
1.3 Assess sex differences in the prevalence of mental disorders in people with an addictive disorder.
2.1 Evaluate the presence of dysfunctions in the SC of people with dual pathology.
2.2 Evaluate the dysfunctions in the subdomains of SC of people with dual pathology.
2.3 Evaluate the differences in clinical and penitentiary environments in SC dysfunctions in dual pathology.
2.4 Evaluate sex differences in SC dysfunctions in dual pathology.
3.1 Evaluate the effectiveness of the new version of the ET® program in people with dual pathology.
3.2 Evaluate the effectiveness of the new version of the ET® program on therapeutic response: adherence, quality of life, symptom perception, and relapses.
3.3 Evaluate the differences in clinical and prison settings in the effectiveness of treatment with ET®.
3.4 Assess gender differences in the efficacy of ET® treatment.
4.1 Increase the bank of saliva samples for proteomic studies. 4.2 Identify molecular patterns in saliva that are associated with SC dysfunctions.
4.3 Identify biomarkers that predict therapeutic response. 4.4 Evaluate gender differences in the study of biomarkers.
Methodology (subjects, variables, data collection, analysis plan):
To study the presence of SC dysfunctions in a clinical sample of patients treated in drug addiction care facilities, patients with a diagnosis of SUD who begin treatment in care centers in Galicia, Madrid, and Portugal, and in the prison in Cuenca will be recruited to carry out the phase of collecting sociodemographic variables, descriptive data, and psychometric evaluation using the battery described below.
To study the therapeutic efficacy of the ET® program in patients with dual pathology who present SC dysfunctions, a multicenter, longitudinal, prospective, controlled, and randomized multimodal (proteomic, neurocognitive, and clinical) study phase on the effectiveness of ET® will be carried out. Early prediction of response in patients with dual pathology requiring social cognition rehabilitation treatment. The response will be evaluated after 3 months (short term), after 12 sessions where activities on emotions and theory of mind are combined, and a follow-up will be carried out after 12 months (long term).
To identify new biomarkers in saliva, using mass spectrometry techniques (LC-ESI-MS/MS), which contribute to predicting which patients would benefit from receiving therapy with the ET® program, saliva samples will be collected to carry out the proteomic study in all participants in the ET® efficacy trial. To improve the ET® instrument to serve new types of users, both in healthcare and educational environments, and for its future adaptation for commercial exploitation, observations and evaluations of researchers and patients will be recorded to implement potential future ET® improvements.
STUDY POPULATION:
Patients who begin treatment in care facilities of the drug addiction network and prison, who meet the selection criteria specified in the inclusion criteria section and who do not meet any of the exclusion criteria.
NEUROPSYCHOLOGICAL ASSESSMENT (pre and post):
The neuropsychological evaluation time is estimated at 120 minutes. For the proposed protocol, at least 2 evaluation sessions are required:
* The assessment of dual pathology requires a 30-minute session.
* The assessment of social cognition requires 1 session of 30 minutes and 1 session of 60 minutes.
Patients will be evaluated before and after the intervention, and the evaluation will be repeated after 12 months, using the instruments described below:
Clinical evaluation:
* Dual Pathology Screening Interview (ECDD)
* Symptom Checklist-90-R (SCL-90-R)
Assessment of Social Cognition:
* The Interpersonal Reactivity Index (IRI)
* Ekman 60 Faces Test
* Movie for the Assessment of Social Cognition (MASC)
* Marlowe-Crowne Social Desirability Scale (MCSDS)
* Ambiguous Intentions Hostility Questionnaire (AIHQ)
